RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

Gfp:

Re: Anavex. I've known Christopher Missling for--must be about fifteen years now. I'm curious about sigma-1 as a target, it has had something of a resurgence of interest after being forgotten/neglected for a while (not unlike AMPA receptors). But, Anavex being cash-strapped, they are relying upon biomarkers which are not viewed as meaningful by the AD community, and small-scale open-label studies do nothing more than assess safety and patient suggestibility. It's too bad he doesnt have the money to pay for a reasonably scaled Phase II, it would be interesting to see what the drug could do.

NeuroPerspective